But as adoption has surged, a new set of questions has emerged: What does it feel like to take these medications
Trade-offs: Fluid retention risk (and other contraindications), slower onset (weeks to months), and careful patient selection
Anal Biochem 414(2):208214 Beutler HO (1990) l-glutamate, colorimetric method with glutamate dehydrogenase and diaphorase
Relevant Studies & Resources For those interested in learning more about the research behind IGF-1, IGFBP-3, and their connection to cancer risk and hormone signaling, here are several peer-reviewed studies and academic resources: Circulating Growth Factor Concentrations and Breast Cancer Risk: A Nested Case-Control Study of IGF-1, IGFBP-3, and Breast Cancer in a Family-Based Cohort PMC Insulin-like Growth Factor (IGF)-I, IGF Binding Protein-3, and Cancer Risk: Systematic Review and Meta-Regression Analysis PubMed The Expression and Function of IGFBP-3 in Normal and Malignant Breast Tissue Anticancer Research IGF-1, IGFBP-3, and Cancer Risk The Lancet Concentrations of IGF-I and IGFBP-3 and Pancreatic Cancer Risk in the European Prospective Investigation into Cancer and Nutrition British Journal of Cancer Genetic Polymorphisms in the IGFBP3 Gene: Association with Breast Cancer Risk and Blood IGFBP-3 Protein Levels Among Chinese Women Cancer Epidemiology, Biomarkers & Prevention Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: A Case-Control Analysis Journal of the National Cancer Institute Alterations of Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Glycosylation in Patients with Breast Tumours Clinical Biochemistry
Song Y, Huang Y, Zhou F, Ding J, Zhou W (2022) Macrophage-targeted nanomedicine for chronic diseases immunotherapy
